Radioimmunotherapy of Glioblastoma by Using 1-131 and Y-90 Labeled Antitenascin Monoclonal Antibodies View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1999

AUTHORS

Pietro Riva , Giancarlo Franceschi , Massimo Frattarelli , Nada Riva , Guiducci , Anna Maria Cremonini , Giuliano Giuliani , Michela Casi , Rossella Gentile

ABSTRACT

BC-2 and BC-4 Mabs labelled with 1-131, were given directly in the tumoral bed. 81 glioblastoma evaluable cases were treated. Adverse effects were very few. The treatment lengthened the patients’ median survival (22 months in total). 11 PR, 1 CR and 24 NED (No Evidence of Disease) were recorded. The response rate was 44.4 %. Then a new isotope, Y-90, has been employed. Following a phase I trial, a phase II study was initiated in 22 cases with malignant glioma (anaplastic astrocytoma n.6 and glioblastoma n.16). In 16evaluable patients (12 glioblastoma and 4 anaplastic astrocytoma) the objective response consisted in 1 PD, 4 SD,7 PR,2 CR and 2 NED.The global response rate (PR+ CR+NED) was 68.75% (66.6% in glioblastoma and 75% in anaplastic astrocytoma group). More... »

PAGES

59-63

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-0348-8782-3_8

DOI

http://dx.doi.org/10.1007/978-3-0348-8782-3_8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001180984


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riva", 
        "givenName": "Pietro", 
        "id": "sg:person.01177547630.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177547630.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Franceschi", 
        "givenName": "Giancarlo", 
        "id": "sg:person.01371354664.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371354664.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurosurgery Dept., \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Neurosurgery Dept., \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Frattarelli", 
        "givenName": "Massimo", 
        "id": "sg:person.01322326452.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322326452.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riva", 
        "givenName": "Nada", 
        "id": "sg:person.0646254024.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646254024.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurosurgery Dept., \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Neurosurgery Dept., \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guiducci", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurosurgery Dept., \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Neurosurgery Dept., \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cremonini", 
        "givenName": "Anna Maria", 
        "id": "sg:person.0713444625.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713444625.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurosurgery Dept., \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Neurosurgery Dept., \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giuliani", 
        "givenName": "Giuliano", 
        "id": "sg:person.01072521557.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072521557.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Casi", 
        "givenName": "Michela", 
        "id": "sg:person.01347076462.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347076462.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414682.d", 
          "name": [
            "Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, \u201cM.Bufalini\u201d Hospital, 47023, Cesena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gentile", 
        "givenName": "Rossella", 
        "id": "sg:person.0610473175.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610473175.11"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1999", 
    "datePublishedReg": "1999-01-01", 
    "description": "BC-2 and BC-4 Mabs labelled with 1-131, were given directly in the tumoral bed. 81 glioblastoma evaluable cases were treated. Adverse effects were very few. The treatment lengthened the patients\u2019 median survival (22 months in total). 11 PR, 1 CR and 24 NED (No Evidence of Disease) were recorded. The response rate was 44.4 %. Then a new isotope, Y-90, has been employed. Following a phase I trial, a phase II study was initiated in 22 cases with malignant glioma (anaplastic astrocytoma n.6 and glioblastoma n.16). In 16evaluable patients (12 glioblastoma and 4 anaplastic astrocytoma) the objective response consisted in 1 PD, 4 SD,7 PR,2 CR and 2 NED.The global response rate (PR+ CR+NED) was 68.75% (66.6% in glioblastoma and 75% in anaplastic astrocytoma group).", 
    "editor": [
      {
        "familyName": "Bergmann", 
        "givenName": "Helmar", 
        "type": "Person"
      }, 
      {
        "familyName": "K\u00f6hn", 
        "givenName": "Horst", 
        "type": "Person"
      }, 
      {
        "familyName": "Sinzinger", 
        "givenName": "Helmut", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-0348-8782-3_8", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-0348-9772-3", 
        "978-3-0348-8782-3"
      ], 
      "name": "Radioactive Isotopes in Clinical Medicine and Research XXIII", 
      "type": "Book"
    }, 
    "keywords": [
      "response rate", 
      "global response rate", 
      "antitenascin monoclonal antibody", 
      "phase II study", 
      "phase I trial", 
      "median survival", 
      "objective response", 
      "evaluable cases", 
      "tumoral bed", 
      "malignant gliomas", 
      "monoclonal antibodies", 
      "adverse effects", 
      "patients", 
      "radioimmunotherapy", 
      "gliomas", 
      "NED", 
      "trials", 
      "glioblastoma", 
      "mAbs", 
      "antibodies", 
      "survival", 
      "treatment", 
      "cases", 
      "Y-90", 
      "rate", 
      "response", 
      "BC-2", 
      "study", 
      "effect", 
      "PR", 
      "bed", 
      "Pd", 
      "Cr", 
      "new isotopes", 
      "isotopes", 
      "BC-4 Mabs", 
      "glioblastoma evaluable cases", 
      "I trial", 
      "II study", 
      "Radioimmunotherapy of Glioblastoma", 
      "Y-90 Labeled Antitenascin Monoclonal Antibodies", 
      "Labeled Antitenascin Monoclonal Antibodies"
    ], 
    "name": "Radioimmunotherapy of Glioblastoma by Using 1-131 and Y-90 Labeled Antitenascin Monoclonal Antibodies", 
    "pagination": "59-63", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001180984"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-0348-8782-3_8"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-0348-8782-3_8", 
      "https://app.dimensions.ai/details/publication/pub.1001180984"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-01-01T19:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/chapter/chapter_104.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-0348-8782-3_8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-0348-8782-3_8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-0348-8782-3_8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-0348-8782-3_8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-0348-8782-3_8'


 

This table displays all metadata directly associated to this object as RDF triples.

168 TRIPLES      23 PREDICATES      68 URIs      61 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-0348-8782-3_8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N87415b53f45249a7866b431d2943aa93
4 schema:datePublished 1999
5 schema:datePublishedReg 1999-01-01
6 schema:description BC-2 and BC-4 Mabs labelled with 1-131, were given directly in the tumoral bed. 81 glioblastoma evaluable cases were treated. Adverse effects were very few. The treatment lengthened the patients’ median survival (22 months in total). 11 PR, 1 CR and 24 NED (No Evidence of Disease) were recorded. The response rate was 44.4 %. Then a new isotope, Y-90, has been employed. Following a phase I trial, a phase II study was initiated in 22 cases with malignant glioma (anaplastic astrocytoma n.6 and glioblastoma n.16). In 16evaluable patients (12 glioblastoma and 4 anaplastic astrocytoma) the objective response consisted in 1 PD, 4 SD,7 PR,2 CR and 2 NED.The global response rate (PR+ CR+NED) was 68.75% (66.6% in glioblastoma and 75% in anaplastic astrocytoma group).
7 schema:editor N42a2288e76e14ec8ac436d52eb3eaab5
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf Nc1918b1ac67047d0bf186c63247cf822
12 schema:keywords BC-2
13 BC-4 Mabs
14 Cr
15 I trial
16 II study
17 Labeled Antitenascin Monoclonal Antibodies
18 NED
19 PR
20 Pd
21 Radioimmunotherapy of Glioblastoma
22 Y-90
23 Y-90 Labeled Antitenascin Monoclonal Antibodies
24 adverse effects
25 antibodies
26 antitenascin monoclonal antibody
27 bed
28 cases
29 effect
30 evaluable cases
31 glioblastoma
32 glioblastoma evaluable cases
33 gliomas
34 global response rate
35 isotopes
36 mAbs
37 malignant gliomas
38 median survival
39 monoclonal antibodies
40 new isotopes
41 objective response
42 patients
43 phase I trial
44 phase II study
45 radioimmunotherapy
46 rate
47 response
48 response rate
49 study
50 survival
51 treatment
52 trials
53 tumoral bed
54 schema:name Radioimmunotherapy of Glioblastoma by Using 1-131 and Y-90 Labeled Antitenascin Monoclonal Antibodies
55 schema:pagination 59-63
56 schema:productId Ne6eb7ceb9be044bcab57be093707e753
57 Nf919c0d18c124f3fb384f2694c0b16f1
58 schema:publisher N0c1dc87befdd4460be03a8e649072642
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001180984
60 https://doi.org/10.1007/978-3-0348-8782-3_8
61 schema:sdDatePublished 2022-01-01T19:06
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher Nb9c970d60cd04e0a8abe55f1e8880367
64 schema:url https://doi.org/10.1007/978-3-0348-8782-3_8
65 sgo:license sg:explorer/license/
66 sgo:sdDataset chapters
67 rdf:type schema:Chapter
68 N0c1dc87befdd4460be03a8e649072642 schema:name Springer Nature
69 rdf:type schema:Organisation
70 N16ed0eae881d4beebcf3996f338346f3 schema:familyName Köhn
71 schema:givenName Horst
72 rdf:type schema:Person
73 N2c7a8ae8377049a8a61ea09e8ca31ec2 rdf:first sg:person.0646254024.48
74 rdf:rest N53d3bdcd02344558980bd83a01fb56d3
75 N3115248405d44f129cacf130189a80c0 rdf:first Nf57042082c90473fb490df60de8f8640
76 rdf:rest rdf:nil
77 N3dab1a33f7394ca1bf581f503e4cfc2a rdf:first sg:person.01347076462.98
78 rdf:rest N6b219179765a4bd7906cb5ff00ac0c4d
79 N42a2288e76e14ec8ac436d52eb3eaab5 rdf:first Nf6e76b4433b743b982a7a5beb362c3d1
80 rdf:rest Nfb2a0419bcb74bbd85eb48a37b544cd5
81 N47892f895bdf4d71bfbc94f2e2bb1c42 schema:affiliation grid-institutes:grid.414682.d
82 schema:familyName Guiducci
83 rdf:type schema:Person
84 N53d3bdcd02344558980bd83a01fb56d3 rdf:first N47892f895bdf4d71bfbc94f2e2bb1c42
85 rdf:rest N8b6a7fda2357441cb03620cf6fc8a322
86 N6b219179765a4bd7906cb5ff00ac0c4d rdf:first sg:person.0610473175.11
87 rdf:rest rdf:nil
88 N87415b53f45249a7866b431d2943aa93 rdf:first sg:person.01177547630.17
89 rdf:rest Nf09c0317895842948e35be81aecfc675
90 N8b6a7fda2357441cb03620cf6fc8a322 rdf:first sg:person.0713444625.12
91 rdf:rest Nf11383642f5a40f98105147c9ecbd638
92 Nb8ae3e6602ef45b6b0bf1f1d253e13e4 rdf:first sg:person.01322326452.21
93 rdf:rest N2c7a8ae8377049a8a61ea09e8ca31ec2
94 Nb9c970d60cd04e0a8abe55f1e8880367 schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 Nc1918b1ac67047d0bf186c63247cf822 schema:isbn 978-3-0348-8782-3
97 978-3-0348-9772-3
98 schema:name Radioactive Isotopes in Clinical Medicine and Research XXIII
99 rdf:type schema:Book
100 Ne6eb7ceb9be044bcab57be093707e753 schema:name doi
101 schema:value 10.1007/978-3-0348-8782-3_8
102 rdf:type schema:PropertyValue
103 Nf09c0317895842948e35be81aecfc675 rdf:first sg:person.01371354664.54
104 rdf:rest Nb8ae3e6602ef45b6b0bf1f1d253e13e4
105 Nf11383642f5a40f98105147c9ecbd638 rdf:first sg:person.01072521557.86
106 rdf:rest N3dab1a33f7394ca1bf581f503e4cfc2a
107 Nf57042082c90473fb490df60de8f8640 schema:familyName Sinzinger
108 schema:givenName Helmut
109 rdf:type schema:Person
110 Nf6e76b4433b743b982a7a5beb362c3d1 schema:familyName Bergmann
111 schema:givenName Helmar
112 rdf:type schema:Person
113 Nf919c0d18c124f3fb384f2694c0b16f1 schema:name dimensions_id
114 schema:value pub.1001180984
115 rdf:type schema:PropertyValue
116 Nfb2a0419bcb74bbd85eb48a37b544cd5 rdf:first N16ed0eae881d4beebcf3996f338346f3
117 rdf:rest N3115248405d44f129cacf130189a80c0
118 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
119 schema:name Medical and Health Sciences
120 rdf:type schema:DefinedTerm
121 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
122 schema:name Clinical Sciences
123 rdf:type schema:DefinedTerm
124 sg:person.01072521557.86 schema:affiliation grid-institutes:grid.414682.d
125 schema:familyName Giuliani
126 schema:givenName Giuliano
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072521557.86
128 rdf:type schema:Person
129 sg:person.01177547630.17 schema:affiliation grid-institutes:grid.414682.d
130 schema:familyName Riva
131 schema:givenName Pietro
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177547630.17
133 rdf:type schema:Person
134 sg:person.01322326452.21 schema:affiliation grid-institutes:grid.414682.d
135 schema:familyName Frattarelli
136 schema:givenName Massimo
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322326452.21
138 rdf:type schema:Person
139 sg:person.01347076462.98 schema:affiliation grid-institutes:grid.414682.d
140 schema:familyName Casi
141 schema:givenName Michela
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347076462.98
143 rdf:type schema:Person
144 sg:person.01371354664.54 schema:affiliation grid-institutes:grid.414682.d
145 schema:familyName Franceschi
146 schema:givenName Giancarlo
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371354664.54
148 rdf:type schema:Person
149 sg:person.0610473175.11 schema:affiliation grid-institutes:grid.414682.d
150 schema:familyName Gentile
151 schema:givenName Rossella
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610473175.11
153 rdf:type schema:Person
154 sg:person.0646254024.48 schema:affiliation grid-institutes:grid.414682.d
155 schema:familyName Riva
156 schema:givenName Nada
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646254024.48
158 rdf:type schema:Person
159 sg:person.0713444625.12 schema:affiliation grid-institutes:grid.414682.d
160 schema:familyName Cremonini
161 schema:givenName Anna Maria
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713444625.12
163 rdf:type schema:Person
164 grid-institutes:grid.414682.d schema:alternateName Neurosurgery Dept., “M.Bufalini” Hospital, 47023, Cesena, Italy
165 Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, “M.Bufalini” Hospital, 47023, Cesena, Italy
166 schema:name Neurosurgery Dept., “M.Bufalini” Hospital, 47023, Cesena, Italy
167 Nuclear Medicine Dept. and Istituto Oncologico Romagnolo, “M.Bufalini” Hospital, 47023, Cesena, Italy
168 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...